Latest news
Tenax's oral levosimendan misses primary endpoint in Phase 3 LEVEL PH-HFpEF trial - DealroomDealroom · Mon, 10 Aug 2026 16:55:56 GMTTenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF - AllSciAllSci · Mon, 10 Aug 2026 16:40:47 GMTTenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 15:03:31 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:03:24 GMTTenax trounced by phase 3 heart failure readout - pharmaphorumpharmaphorum · Mon, 10 Aug 2026 14:13:28 GMTTenax shares nosedive as heart failure drug fails in Phase 3 - BioSpaceBioSpace · Mon, 10 Aug 2026 13:00:28 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²TechStock² · Mon, 10 Aug 2026 12:46:29 GMT